Fungal infections remain a major complication after haematopoietic SCT. Patients with GvHD are especially at risk for pulmonary fungal infections. 1 Prophylactic regimens for patients with GvHD include posaconazole 2 and voriconazole, 3 and have demonstrated ability to prevent invasive fungal infections in a majority of patients undergoing allo-SCT for haematological malignancies. However, zygomycetes, Fusarium spp., and other rare moulds may cause major problems due to their resistance to these commonly used antifungal agents.
We report on a 52-year-old Caucasian male with a bcrabl positive Pro-B ALL, who was treated according to the risk adapted German Multicenter Protocol GMALL 07/ 2003 (http://www.kompetenznetz-leukaemie.de/content/ aerzte/studien/studienregister) and underwent allo-SCT with reduced intensity conditioning in January 2010. A grade II acute GvHD of the skin was successfully treated with corticosteroids. In October, the patient was readmitted because of severe diarrhea. Endoscopic examination of the gastrointestinal tract, including multiple biopsies was performed, revealing late onset gastrointestinal acute GvHD grade III. Because of diarrhea and subtherapeutical posaconazole serum levels of 0.24 mg/L, the antifungal prophylaxis was changed to i.v. voriconazole 200 mg twice daily. High-dose corticosteroid treatment with methylprednisone 2 mg/kg per day was initiated, and mycophenolate mofetil dose was increased to 1.5 mg/kg twice daily. Initially, the patient responded well to the treatment, but after 10 days, watery diarrhea reoccurred. Thus, infliximab (10 mg/kg once weekly, two doses) was commenced as third line GvHD therapy. A few days later, the C-reactive protein markedly increased and the patient developed respiratory symptoms, together with an incomplete hemiparesis caused by a stroke. Concurrently, the serum galactomannan index (Bio-Rad Laboratories, Marnes-laCoquette, France) increased from 0.36 to 4.44 OD (normal range o0.5 OD) within a week, and increased up to 420 OD in the following days. A computed tomography scan of the lungs revealed a new infiltrate with a halo sign (Figure 1a) . Broncho-alveolar lavage (BAL) was performed the next day, and the patient was empirically switched to liposomal amphotericin B (5 mg/kg per day) and caspofungin (70 mg per day). Gram stain obtained from BAL revealed fungal hyphae, and cultures from lavage fluid grew a mould (Figure 2a After 7 days of caspofungin and liposomal amphotericin B, the C-reactive protein decreased significantly and a follow-up computed tomography scan revealed the occurrence of a second lesion, whereas the halo sign of the primary infiltrate had resolved (Figure 1b) . However, later in the course, the patient deteriorated and the C-reactive protein increased again. Aside from adaptations of the empiric antibacterial treatment, i.v. itraconazole 200 mg twice daily was added. Despite triple antifungal therapy, the patient ultimately died shortly thereafter due to multiple organ failure as a consequence of refractory acute GvHD with subsequent fungal infection. Swabs from lung and central nervous system obtained during autopsy (Figure 1c) grew many colonies of G. argillacea, indicating that the mould was still viable after more than 2 weeks of antifungal combination treatment. Histology from the central nervous system revealed massive infiltration by G. argillacea (Figure 2c) .
G. argillacea has been reported in the sputum of patients with cystic fibrosis, 4,5 but its pathogenic potential remained largely unknown. The first case of an invasive infection was found in 2009, in a German shepherd dog. 6 It has been suggested that Geosmithia spp. may be more commonly isolated, but can easily be missed because of its morphological similarities to Penicillium and Paecilomyces species. [4] [5] [6] Only very recently, two case series covering nine patients with chronic granulomatous disease were published, 7, 8 including one hematopoietic stem cell transplant recipient. All described isolates had a high minimum inhibition concentration to voriconazole.
To our knowledge, we describe the first case of an invasive fungal infection due to G. argillacea in a haematopetic stem cell transplant recipient without chronic granulomatous disease. Of particular interest in this case was the extremely high level of galactomannan index despite antimycotic therapy, reaching levels above the upper detection limit on six consecutive time points, indicating a breakthrough fungal infection. It is known that fungi other than Aspergillus species show crossreactivity with galactomannan enzyme immunoassay. 9 This is in particular true for other moulds of the Eurotiales like Penicillium and Geosmithia. The high minimum inhibition concentrations to voriconazole and fluconazole pose a major problem in patients with gastrointestinal GvHD, because i.v. formulations are commonly used in for prophylaxis, when administration of oral posaconazole is not possible. Our case illustrates that-despite a typical radiologic pattern and positive serum and BAL galactomannan tests-moulds other than Aspergillus sp. can cause severe infectious complications in these high-risk patients. Microbiological workup such as early BAL 10 is essential to detect these rare infections. In addition, resistance testing is crucial to provide adequate treatment. We conclude that G. argillacea is apparently capable of causing severe infections not only in patients with chronic granulomatous disease, but also in patients with severe GvHD.
